Niagen Bioscience (NAGE) Change in Receivables (2011 - 2020)
Niagen Bioscience (NAGE) posted quarterly Change in Receivables of -$1.3 million for Q1 2020, down 238.7% year-over-year from $956000.0 in Q2 2019, and down 185.77% quarter-over-quarter from $1.5 million in Q4 2019.
Powered by 
Analysis
Niagen Bioscience (NAGE) Change in Receivables (2011 - 2020) Analysis & Trends
Niagen Bioscience (NAGE) has reported Change in Receivables for 8 consecutive years, with -$1.3 million the latest figure, recorded in Q1 2020.
- In Q1 2020, Change in Receivables fell 238.7% year-over-year to -$1.3 million; the TTM figure through Mar 2020 stood at -$2.3 million (down 267.58% YoY), while the FY2019 annual figure was -$44000.0, down 103.96% from the prior year.
- Change in Receivables retreated to -$1.3 million in Q1 2020 per NAGE's latest filing, from $1.5 million in the prior quarter.
- Across five years, Change in Receivables topped out at $1.5 million in Q4 2019 and bottomed at -$2.5 million in Q3 2016.
- Historically, Change in Receivables has averaged -$144236.2 across 5 years, with a median of $129138.0 in 2016.
- Annual changes were most pronounced in 2018 — Change in Receivables soared 366.18% — and 2019, when it tumbled 577.03%.
- Niagen Bioscience's Change in Receivables stood at $181878.0 in 2016, then plunged by 405.15% to -$555000.0 in 2017, then jumped by 174.59% to $414000.0 in 2018, then soared by 273.43% to $1.5 million in 2019, then plunged by 185.77% to -$1.3 million in 2020.
- Business Quant data shows NAGE's Change in Receivables at -$1.3 million in Q1 2020, $1.5 million in Q4 2019, and -$217000.0 in Q3 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | -1.33 Mn |
| Dec 31, 2019 | 1.55 Mn |
| Sep 30, 2019 | -217,000.00 |
| Jun 30, 2019 | -2.33 Mn |
| Mar 31, 2019 | 956,000.00 |
| Dec 31, 2018 | 414,000.00 |
| Sep 30, 2018 | 362,000.00 |
| Jun 30, 2018 | -344,000.00 |
| Mar 31, 2018 | 679,000.00 |
| Dec 30, 2017 | -555,000.00 |
| Sep 30, 2017 | -136,000.00 |
| Jul 1, 2017 | 806,000.00 |
| Apr 1, 2017 | 822,000.00 |
| Dec 31, 2016 | 181,878.00 |
| Oct 1, 2016 | 76,398.00 |
| Jul 2, 2016 | -2.52 Mn |
| Apr 2, 2016 | -1.85 Mn |
| Jan 2, 2016 | 840,309.00 |
| Mar 30, 2013 | 971,153.00 |
| Dec 29, 2012 | -737,110.00 |